07:00 , Jun 3, 2013 |  BC Week In Review  |  Company News

Roche, Areva deal

Macrocyclics Inc., a subsidiary of Areva's Areva Med LLC (Bethesda, Md.) subsidiary, and Roche amended a 2012 deal under which the partners are creating an alpha radio-immunotherapy platform to treat cancer by assessing the efficacy...
07:00 , Jul 30, 2012 |  BC Week In Review  |  Company News

Roche, Areva deal

Areva's Areva Med LLC (Bethesda, Md.) subsidiary partnered with Roche to create an alpha radio-immunotherapy platform to treat cancer. Roche's Pharma Research & Early Development organization (pRED) will assess the efficacy of combining Roche-engineered antibodies...
07:00 , May 14, 2012 |  BC Week In Review  |  Clinical News

212Pb-TCMC-Trastuzumab: Phase I started

Areva Med LLC , Bethesda, Md.   Product: 212Pb-TCMC-Trastuzumab   Business: Cancer   Molecular target: NA   Description: Trastuzumab combined with lead-212 isotope   Indication: Treat cancer that has metastasized the abdominal region   Endpoint:...